No Data
No Data
S.F. Holding's revenue from supply chain and international business increased by about 20% in November, and WUXI APPTEC subscribed to a European biotechnology private equity fund. | Selected announcements from Hong Kong stocks on December 19.
① In November, S.F. Holding's revenue from supply chain and international Business increased by about 20%. How significant is this for the improvement of performance? ② WUXI APPTEC subscribed to a private equity fund in Europe focused on Biotechnology. What are the highlights?
Express News | WuXi AppTec Says Unit Plans to Subscribe for Shares in Two Private Investment Funds With a Total of 20 Mln Euros
WUXI APPTEC (603259.SH): Plans to subscribe to private equity fund shares.
On December 19, Gronhui reported that WUXI APPTEC (603259.SH) announced that its wholly-owned subsidiary WuXiPharmaTechHealthcareFundIL.P. (referred to as "WuXiFundI") plans to subscribe for shares in the fund SOFINNOVABIOVELOCITAIIS.L.P. (referred to as "SofinnovaBiovelocitaII" or "SBVII") as a limited partner, with a subscription amount of 10 million euros (according to the exchange rate announced by the China Forex Trading Center on December 19, 2024).
WuXi AppTec Co., Ltd.'s (SHSE:603259) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Zhongtai: The implementation of the tenth batch of centralized procurement is expected to accelerate the clearance of generic drugs. Commercial insurance is an important incremental logic in the pharmaceutical Sector.
It is recommended to keep a close eye on the progress and implementation of commercial insurance, as improvements in the payment sector are expected to bring about a significant market trend in the Pharmaceutical Sector, with opportunities for recovery and reversal in hospital pharmaceuticals, diagnostics, and Medical Devices.
Express News | UBS Group AG's Long Position in H-Shares of WuXi AppTec Increases to 5.63% on Dec 9 From 4.99% - HKEX